Cargando…
Use of Identical INN “Imiglucerase” for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database
INTRODUCTION: Approved in 1994 and assigned the International Nonproprietary Name (INN) imiglucerase by the World Health Organization, Cerezyme(®) (Sanofi Genzyme) is an enzyme replacement therapy used to treat Gaucher disease in > 90 countries. At least two therapies approved outside the USA and...
Autores principales: | Tsang, So-Fai, Pandya, Shirali, Barakov, Kristina, Keutzer, Joan, Lewis, Grace, Ross, Leorah, Freisens, Selena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857131/ https://www.ncbi.nlm.nih.gov/pubmed/35020177 http://dx.doi.org/10.1007/s40264-021-01125-4 |
Ejemplares similares
-
Mambo Inn : as recorded by Tito Puente /
por: Sampson, Grace
Publicado: (2013) -
Review of the safety and efficacy of imiglucerase treatment of Gaucher disease
por: Elstein, Deborah, et al.
Publicado: (2009) -
Imiglucerase in the treatment of Gaucher disease: a history and perspective
por: Deegan, Patrick B, et al.
Publicado: (2012) -
Jamaica Inn
por: Du Maurier, Daphne, 1907-1989
Publicado: (1962) -
Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1
por: Peterschmitt, M. Judith, et al.
Publicado: (2019)